Episode 522

Alexion Pharmaceuticals SVP & CIO George Llado

January 18, 2021

More Ways to Listen

LISTEN TO PODCAST

Subscribe on Your Favorite Platform

Other Platforms

About the Guest

George Llado

SVP & CIO of Alexion Pharmaceuticals

George Llado is the senior vice president and chief information officer of Alexion Pharmaceuticals, a nearly $5 billion organization focused on serving patients and families affected by rare diseases by providing highly innovative, life-changing therapies for the diseases it treats. Prior to joining Alexion, George spent 25 years at Merck & Co, most recently as vice president.

Episode Overview

522: Alexion Pharmaceuticals SVP & CIO George Llado discusses

The company’s journey from on-premise to the cloud and the benefits that provided
Alexion’s secret sauce to change management
The firm’s close relationship with external partners
Why Alexion invests in smaller companies
The risk George took on Zoom back in 2016
The win-win partnership between Alexion and the smaller companies it invests in and works with
We discuss some of the lessons George has taken from the pandemic
How the social injustices that came to light this year are not new
George’s take on new and emerging digital tools

Among a variety of other topics.

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | Spotify | RSS | More

“"Think about a digital twin that is a human, where I have learned everything that they do, every artery, every cell. I build that digital twin, and I run a trial on that twin and get real results. Now, I do not have to use an animal model, and I do not have to get a get a human in there. I may be able to get results much, much faster. I might be able to get to an outcome from phase one through phase three and approval much quicker. The excitement of thinking about how digital could accelerate the trials is just phenomenal."
"